You are here

Article Text

Article menu

Download PDFPDF

Endometrial cancer
412 BioEndoCar: omics approaches for diagnosis and prognosis of endometrial cancer
Free
  1. E Hafner1,
  2. Š Smrkolj2,
  3. A Romano3,
  4. HMJ Werner3,
  5. A Semczuk4,
  6. S Wawrysiuk4,
  7. A Adamiak-Godlewska4,
  8. D Fishman5;6,
  9. J Vilo5;6,
  10. C Lowy7,
  11. C Schröder7,
  12. J Tokarz8,
  13. V Weinberger9,
  14. M Bednaříková9,
  15. P Vinklerova9,
  16. S Ferrero10,
  17. F Barra10,
  18. I Takač11,
  19. J Knez11 and
  20. T Lanišnik Rižner1
  1. 1Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
  2. 2University Medical Centre Ljubljana, Department of Obstetrics and Gynecology, Ljubljana, Slovenia
  3. 3Department of Obstetrics and Gynecology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands
  4. 4Department of Gynecology, Lublin Medical University, Lublin, Poland
  5. 5Institute of Computer Science, University of Tartu, Tartu, Estonia
  6. 6Quretec Ltd., Tartu, Estonia
  7. 7Sciomics GmbH, Heidelberg, Germany
  8. 8Institute for Diabetes and Cancer, Helmholtz Zentrum, Munich, Germany
  9. 9Department of Gynecology and Obstetrics, University Hospital Brno, Brno, Czech Republic
  10. 10Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
  11. 11University Medical Centre Maribor, Division of Gynecology and Perinatology, Maribor, Slovenia

Abstract

Introduction/Background*Endometrial cancer is the second most common carcinoma of the female genital tract globally, and its incidence is still increasing. Optimal treatment of EC depends on early diagnostics and pre-operative stratification to appropriately select the extent of surgery and to plan further therapeutic approach. Current diagnosis and treatment of EC patients is guided by histopathological and surgical findings since there are no accurate non-invasive diagnostic or prognostic methods available. The lack of non-invasive diagnostic and prognostic biomarkers of EC is addressed in the current clinical study titled ‘Biomarkers for Diagnosis and Prognosis of Endometrial Carcinoma’ (NCT03553589).

Methodology Patient recruitment takes place at six medical centers (University Medical Centre Ljubljana, Slovenia; University Medical Centre Maribor, Slovenia; Maastricht University Medical Centre, The Netherlands; Lublin Medical University, Poland; University Hospital Brno, Czech Republic, University of Genoa, Italy).

Plasma samples from women with diagnosed EC and controls will be examined using non-targeted and targeted metabolomics and targeted proteomics approaches. Combined blood metabolome (>850 metabolites), proteome (>900 proteins), clinical and epidemiological data will be analyzed in order to construct diagnostic/prognostic algorithms for early diagnosis of EC and to identify patients with low/high risk for cancer progression and recurrence.

BioEndoCar consortium has defined inclusion/exclusion criteria and a strict standard operating procedure for sample collection, processing and storage that is followed in all medical centers.

Result(s)*Since the beginning of the project we recruited more than 440 patients. Discovery proteomics and discovery metabolomics phase have been concluded. Targeted proteomics and targeted metabolomics analysis are currently in progress and we are awaiting the results.

Conclusion*Within the project we expect to find different metabolic and protein profiles in patients with early stages of EC as compared to controls and in patients with poor prognosis and high risk of disease progression and recurrence as compared to those with favorable prognosis.

Great effort was put into informing the lay and expert public about the importance of the translational studies in EC. We have established an official website (https://bioendocar.eu/), Twitter profile and Facebook page (https://www.facebook.com/bioendocar) where we post all news concerning the project.

Funded by ERA-NET Transcan2 and MIZS.

Nothing to disclose.

http://dx.doi.org/10.1136/ijgc-2021-ESGO.141

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.